Interleukin-23 Antagonists

Interleukin-23 Antagonist

Psoriasis

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Guselkumab, an interleukin-23 antagonist, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. Guselkumab is produced in a mammalian cell line using recombinant DNA technology and has an approximate molecular weight of approximately 147 kDa.</p><p>TREMFYA   <span class="Sup">®</span>(guselkumab) injection is a sterile, preservative free, clear, and colorless to light yellow solution. </p><div class="Section" data-sectioncode="42229-5"><a name="section-9.1"></a><p></p><p class="First"><span class="Underline">TREMFYA for Subcutaneous Injection</span></p><p>Available as a 100 mg/mL solution in a 1 mL or 2 mL glass prefilled syringe, in a 2 mL prefilled pen, or in a 1 mL One-Press patient-controlled injector for subcutaneous use.</p><p>Each TREMFYA 1 mL prefilled syringe or One-Press patient-controlled injector delivers 100 mg guselkumab, L-histidine (0.6 mg), L-histidine monohydrochloride monohydrate (1.5 mg), polysorbate 80 (0.5 mg), sucrose (79 mg) and water for injection at pH 5.8.</p><p>Each TREMFYA 2 mL prefilled syringe or prefilled pen (TREMFYA PEN) delivers 200 mg guselkumab, L-histidine (1.2 mg), L-histidine monohydrochloride monohydrate (3 mg), polysorbate 80 (1 mg), sucrose (158 mg) and water for injection at pH 5.8.</p></div><div class="Section" data-sectioncode="42229-5"><a name="section-9.2"></a><p></p><p class="First"><span class="Underline">TREMFYA for Intravenous Infusion</span></p><p>Available as 10 mg/mL solution in a 20 mL single-dose vial for intravenous use.</p><p>Each TREMFYA 20 mL vial delivers 200 mg guselkumab, EDTA disodium dihydrate (0.4 mg), L-histidine (11.3 mg), L-histidine monohydrochloride monohydrate (26.6 mg), L-methionine (8 mg), polysorbate 80 (10 mg), sucrose (1700 mg) and water for injection at pH 5.8.</p></div></section>

TREMFYA

guselkumab

Tremfya

1 ML guselkumab 100 MG/ML Prefilled Syringe

1 ML guselkumab 100 MG/ML Prefilled Syringe [Tremfya]

1 ML guselkumab 100 MG/ML Auto-Injector

1 ML guselkumab 100 MG/ML Auto-Injector [Tremfya]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Tremfya, an interleukin inhibitor, is indicated for the treatment of plaque psoriasis or psoriatic arthritis in adults. Patients can learn to self-administer Tremfya subcutaneously every eight weeks, and the most common side effects are injection site reactions and an elevated risk of infection.

Tremfya is FDA approved for the following indications: Plaque Psoriasis and Psoriatic Arthritis. 


Report Adverse Event 

Prescribing Information

Prescribing Information - Spanish

Medication Guide 

Submit MSL Request 

Pharmacy List 

Formulary Coverage: Plaque Psoriasis

Formulary Coverage: Psoriatic Arthritis 

Biling & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity 

Letter of Medical Necessity (Reverification)

PA Checklist 

PA Checklist - Spanish

Formulary Exceptions Checklist 

Formulary Exceptions Checklist - Spanish

Formulary Exception Letter 

Appeals Checklist 

Appeals Checklist - Spanish

Janssen CarePath Provider Portal

Business Associate Agreement - HCP Office 

Patient Authorization Form - To be Signed by Patient if HCP Office has no BAA with Janssen 